Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase II/III trial of CB03-154 in adults with amyotrophic lateral sclerosis
CTR20253127Phase 3Active
- Sponsor
- Zhimeng Biopharma
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of CB03-154 in amyotrophic lateral sclerosis (ALS), sponsored by Zhimeng Biopharma. Started Oct 2025; status: active.
02
Drugs
CB03-154
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20253127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253127.